

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)



(10) International Publication Number
WO 2023/139557 A1

(51) International Patent Classification:

C12N 15/10 (2006.01) *A61P 7/00* (2006.01)
C12N 9/22 (2006.01) *A61P 21/00* (2006.01)
A61P 3/00 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/IB2023/050560

(22) International Filing Date:

23 January 2023 (23.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/302,271 24 January 2022 (24.01.2022) US
63/386,061 05 December 2022 (05.12.2022) US

(71) Applicant: **LIFEEDIT THERAPEUTICS, INC.**

[US/US]; 507 Airport Boulevard, Suite 101, Morrisville,
North Carolina 27560 (US).

(72) Inventors: **ARYA, Gunjan H.**; 8544 Rosiere Drive, Cary,
North Carolina 27518 (US). **COYLE, Michael**; 407 Elliot
Road, Chapel Hill, North Carolina 27514 (US). **CRAW-**
LEY, Alexandra Briner; 1220 Scott Pl., Cary, North Car-
olina 27511 (US). **ELICH, Tedd D.**; 5 Alumwood Place,
Durham, North Carolina 27705 (US). **PARKER, Joel S.**;
2651 Tosca Trail, Apex, North Carolina 27502 (US).

(74) Agent: **BUCK, B. Logan** et al.; Womble Bond Dickinson
(US) LLP, P.O. Box 7037, Atlanta, Georgia 30357-0037
(US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

(54) Title: RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE




FIGURE 1

(57) Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.

[Continued on next page]

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*